6CM
AGRX

683 Capital Management’s Agile Therapeutics AGRX Stock Holding History

683 Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-37
Closed -$183K – 191
2019
Q4 		$183K Sell
37
-151
-80% -$527K 0.02% 119
2019
Q3 		$444K Buy
+188
New +$463K 0.05% 99

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's AGRX Position: Q1 2020 in Review

683 Capital Management sold out of Agile Therapeutics (AGRX) in Q1 2020, closing a stake of 37 shares — an estimated $183K sold.

683 Capital Management first reported a position in AGRX in Q3 2019 and held it in 2 quarters. The position peaked at $444K in Q3 2019. 61 funds tracked by Wall St. Rank hold AGRX as of Q1 2020.

  • 683 Capital Management reported no remaining Agile Therapeutics position as of Q1 2020 after selling out during the quarter.
  • 683 Capital Management sold 37 Agile Therapeutics shares in Q1 2020, an estimated $183K.
  • 683 Capital Management first reported a position in Agile Therapeutics in Q3 2019 and held it in 2 quarters.
  • 683 Capital Management's Agile Therapeutics position peaked at $444K in Q3 2019.
  • 61 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.